IL297304A - Composition for the treatment of respiratory symptoms and methods thereof - Google Patents

Composition for the treatment of respiratory symptoms and methods thereof

Info

Publication number
IL297304A
IL297304A IL297304A IL29730422A IL297304A IL 297304 A IL297304 A IL 297304A IL 297304 A IL297304 A IL 297304A IL 29730422 A IL29730422 A IL 29730422A IL 297304 A IL297304 A IL 297304A
Authority
IL
Israel
Prior art keywords
treatment
composition
methods
respiratory symptoms
respiratory
Prior art date
Application number
IL297304A
Other languages
Hebrew (he)
Inventor
Molad Ami
Original Assignee
Molad Ami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molad Ami filed Critical Molad Ami
Publication of IL297304A publication Critical patent/IL297304A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL297304A 2020-04-14 2022-10-13 Composition for the treatment of respiratory symptoms and methods thereof IL297304A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009499P 2020-04-14 2020-04-14
PCT/IL2021/050428 WO2021209998A1 (en) 2020-04-14 2021-04-14 Composition for the treatment of respiratory symptoms and methods thereof

Publications (1)

Publication Number Publication Date
IL297304A true IL297304A (en) 2022-12-01

Family

ID=78084378

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297304A IL297304A (en) 2020-04-14 2022-10-13 Composition for the treatment of respiratory symptoms and methods thereof

Country Status (2)

Country Link
IL (1) IL297304A (en)
WO (1) WO2021209998A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230097100A (en) * 2020-10-29 2023-06-30 아우랑제브 나피스 나지 Compositions and methods for treating acute respiratory failure and/or acute respiratory distress syndrome using tetrahydrocannabinol and compositions containing the same

Also Published As

Publication number Publication date
WO2021209998A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
IL288061A (en) Compounds and methods for the treatment of covid-19
IL271117B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
IL273388A (en) Compositions and methods for treating and ameliorating respiratory conditions and inflammation of mucosa
IL275678A (en) Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension
IL284414A (en) Methods and compositions for the treatment of fabry disease
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
IL308221A (en) Compositions and methods for the treatment of depression
EP4171606A4 (en) Compositions and methods for the treatment of covid-19
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL283469A (en) Inhalable compositions for use in the treatment of pulmonary diseases
IL297304A (en) Composition for the treatment of respiratory symptoms and methods thereof
EP3877383A4 (en) Compounds and compositions for the treatment of respiratory diseases
PT3937949T (en) Phytoecdysones and the derivatives thereof for use in the treatment of impaired lung function
EP3534713A4 (en) Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases
GB202217355D0 (en) Methods for the prophylaxis and treatment of Covid and Covid-19
PT3911347T (en) Composition for the treatment and/or prevention of lower urinary tract symptoms
SG10201902000YA (en) Isthmin 1 for treatment of lung inflammation
IL311581A (en) Compositions and methods for the treatment of pcdh19 related disorders
IL280868A (en) Compositions and methods for treatment of acute lung injury
AU2018904242A0 (en) Compounds and compositions for the treatment of respiratory diseases
AU2019901150A0 (en) Compositions and methods of treatment of respiratory tract infections
EP3846792A4 (en) Methods and compositions for treatment of asthma or parkinson's disease
GB202110146D0 (en) Treatment of respiratory conditions
AU2019900514A0 (en) Compositions and methods for treating respiratory diseases
EP3890765A4 (en) Methods and compositions for the treatment of sengers syndrome